You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCalcium Acetate
Accession NumberDB00258  (APRD00839)
TypeSmall Molecule
GroupsApproved
DescriptionThe chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]
Structure
Thumb
Synonyms
Acetate OF lime
Brown acetate of lime
Ca(oac)2
calcium ethanoate
calcium(II) acetate
Gray acetate of lime
Lime acetate
Lime pyrolignite
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium AcetateCapsule667 mg/1OralSandoz Inc2012-03-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Calcium AcetateCapsule667 mg/1OralSandoz Inc2012-03-14Not applicableUs
PhosloCapsule667 mg/1OralPhysicians Total Care, Inc.2010-03-01Not applicableUs
PhosloCapsule667 mg/1OralFresenius Medical Care North America2001-04-02Not applicableUs
PhosloCapsule667 mg/1OralCardinal Health2001-04-02Not applicableUs
Phoslo TabletsTablet667 mgOralFresenius Medical Care North America2006-02-222013-07-29Canada
PhoslyraSolution667 mg/5mLOralFresenius Medical Care North America2011-04-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium AcetateTablet667 mg/1OralCamber Pharmaceuticals, Inc.2014-02-03Not applicableUs
Calcium AcetateCapsule667 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Calcium AcetateCapsule667 mg/1OralMajor Pharmaceuticals2014-10-08Not applicableUs
Calcium AcetateCapsule667 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Calcium AcetateCapsule667 mg/1OralClinical Solutions Wholesale2012-03-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralHeritage Pharmaceuticals Inc.2015-07-07Not applicableUs
Calcium AcetateTablet667 mg/1OralZydus Pharmaceuticals USA Inc.2012-02-23Not applicableUs
Calcium AcetateCapsule667 mg/1OralLUPIN LIMITED2015-09-09Not applicableUs
Calcium AcetateTablet667 mg/1OralSafecor Health, LLC2014-08-15Not applicableUs
Calcium AcetateCapsule667 mg/1OralAmneal Pharmaceuticals of New York, LLC2014-10-08Not applicableUs
Calcium AcetateCapsule667 mg/1OralAtlantic Biologicals Corps2014-02-03Not applicableUs
Calcium AcetateTablet667 mg/1OralPaddock Laboratories, LLC2011-09-13Not applicableUs
Calcium AcetateCapsule667 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Calcium AcetateCapsule667 mg/1OralNostrum Laboratories, Inc.2015-10-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralMc Kesson Contract Packaging2013-04-09Not applicableUs
Calcium AcetateCapsule667 mg/1OralGolden State Medical Supply, Inc.2015-12-22Not applicableUs
Calcium AcetateCapsule667 mg/1OralREMEDYREPACK INC.2010-11-112016-10-13Us
Calcium AcetateCapsule667 mg/1OralAmerican Health Packaging2012-08-27Not applicableUs
Calcium AcetateCapsule667 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-09-01Not applicableUs
Calcium AcetateCapsule667 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralCardinal Health2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralLupin Pharmaceuticals, Inc.2015-09-09Not applicableUs
Calcium AcetateCapsule667 mg/1OralCamber Pharmaceuticals, Inc.2014-02-03Not applicableUs
Calcium AcetateCapsule667 mg/1OralExelan Pharmaceuticals, Inc.2014-04-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralWest Ward Pharmaceuticals Corp.2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralAv Pak2015-11-16Not applicableUs
Calcium AcetateCapsule667 mg/1OralAtlantic Biologicals Corps2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralZydus Pharmaceuticals USA Inc.2015-07-07Not applicableUs
Calcium AcetateCapsule667 mg/1OralCipla Usa Inc.,2016-07-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralCardinal Health2013-07-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralAv Kare, Inc.2015-04-09Not applicableUs
EliphosTablet667 mg/1OralKAISER FOUNDATION HOSPITALS2011-08-24Not applicableUs
EliphosTablet667 mg/1OralHawthorn Pharmaceutical, Inc.2009-02-01Not applicableUs
EliphosTablet667 mg/1OralCarilion Materials Management2009-02-01Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetate Tab 667mgTablet667 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Unapproved/Other Products Not Available
International Brands
NameCompany
TeltozanNot Available
Brand mixtures
NameLabellerIngredients
Aluminum Acetate AstringentTagi Pharma Incorporated
AstringentTAGI Pharma Inc.
DomeboroMOBERG PHARMA NORTH AMERICA LLC
Hyperlyte (multi-electrolyte Concentrate)B. Braun Medical Inc
LypholytePharmaceutical Partners Of Canada Inc
Lypholyte Multi-electrolyte Conc InjLyphomed, Division Of Fujisawa Canada Inc.
NutrilyteAmerican Regent, Inc.
Zo Medical Zo Post Procedure Recovery SystemZO Skin Health, Inc.
Salts
Name/CASStructureProperties
Calcium acetate monohydrate
5743-26-0
Thumb
  • InChI Key: XQKKWWCELHKGKB-UHFFFAOYSA-L
  • Monoisotopic Mass: 175.9997643
  • Average Mass: 176.181
DBSALT001536
Categories
UNIIY882YXF34X
CAS number62-54-4
WeightAverage: 158.166
Monoisotopic: 157.989199835
Chemical FormulaC4H6CaO4
InChI KeyVSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
calcium diacetate
SMILES
[Ca++].CC([O-])=O.CC([O-])=O
Pharmacology
IndicationCalcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Structured Indications
PharmacodynamicsPatients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mechanism of actionCalcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
TargetKindPharmacological actionActionsOrganismUniProt ID
PhosphateSmall moleculeyes
binder
Humannot applicabledetails
Related Articles
Absorption40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCalcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium Acetate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Acetate.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Alfacalcidol.Approved, Nutraceutical
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Acetate.Approved
AnvirzelCalcium Acetate may increase the arrhythmogenic activities of Anvirzel.Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Acetate.Approved
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium Acetate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Acetate.Approved
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Acetate.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.Approved, Withdrawn
CaiThe therapeutic efficacy of Cai can be decreased when used in combination with Calcium Acetate.Investigational
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcitriol.Approved, Nutraceutical
CalciumThe risk or severity of adverse effects can be increased when Calcium is combined with Calcium Acetate.Nutraceutical
Calcium carbonateThe risk or severity of adverse effects can be increased when Calcium carbonate is combined with Calcium Acetate.Approved
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcium Acetate.Approved
Calcium citrateThe risk or severity of adverse effects can be increased when Calcium citrate is combined with Calcium Acetate.Approved
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcium Acetate.Approved
Calcium GluceptateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcium Acetate.Approved
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcium Acetate.Approved, Vet Approved
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium Acetate.Approved, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Acetate.Approved
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Acetate.Approved
CinoxacinCalcium Acetate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
CiprofloxacinCalcium Acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Acetate.Approved
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Calcium Acetate.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Acetate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Acetate.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium Acetate.Approved
DeslanosideCalcium Acetate may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCalcium Acetate may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinCalcium Acetate may increase the arrhythmogenic activities of Digoxin.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Acetate.Approved
Dipotassium phosphateCalcium Acetate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Acetate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Acetate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Acetate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Acetate.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Acetate.Approved
EnoxacinCalcium Acetate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Acetate.Approved, Investigational
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium Acetate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Acetate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Acetate.Withdrawn
FleroxacinCalcium Acetate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium Acetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Acetate.Approved
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Acetate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Acetate.Investigational
GarenoxacinCalcium Acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Acetate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium Acetate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GrepafloxacinCalcium Acetate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Acetate.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Acetate.Approved
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
LevofloxacinCalcium Acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Acetate.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Acetate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Acetate.Approved
Lipoic AcidCalcium Acetate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LomefloxacinCalcium Acetate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Acetate.Approved, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Acetate.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
MetolazoneMetolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Acetate.Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational
MoxifloxacinCalcium Acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Acetate.Investigational
Nalidixic AcidCalcium Acetate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NemonoxacinCalcium Acetate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Acetate.Approved
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Acetate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Acetate.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Acetate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Acetate.Approved
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Acetate.Approved, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Acetate.Approved
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Acetate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.Approved
NorfloxacinCalcium Acetate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinCalcium Acetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OuabainCalcium Acetate may increase the arrhythmogenic activities of Ouabain.Approved
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium Acetate.Approved, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Acetate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium Acetate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Acetate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerhexilineThe therapeutic efficacy of Perhexiline can be decreased when used in combination with Calcium Acetate.Approved
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Acetate.Approved
PolythiazidePolythiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Acetate.Approved, Illicit, Investigational
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Acetate.Withdrawn
PrulifloxacinCalcium Acetate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Acetate.Approved, Investigational
RosoxacinCalcium Acetate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium glycerophosphateCalcium Acetate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium Acetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium Acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Acetate.Approved
Technetium tc 99m etidronateThe serum concentration of Technetium tc 99m etidronate can be decreased when it is combined with Calcium Acetate.Approved
Technetium Tc-99m MedronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Calcium Acetate.Approved
TemafloxacinCalcium Acetate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Acetate.Approved, Vet Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Acetate.Approved
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Calcium Acetate.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Acetate.Approved
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Acetate.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Acetate.Approved
TrovafloxacinCalcium Acetate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Acetate.Investigational
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Acetate.Approved
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Acetate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Acetate.Approved
Food InteractionsNot Available
References
Synthesis Reference

Alan B. Gancy, “Process of making calcium acetate deicing agents and product.” U.S. Patent US4444672, issued November, 1946.

US4444672
General ReferencesNot Available
External Links
ATC CodesV03AE04V03AE07
AHFS Codes
  • 40:18.19
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (25.6 KB)
MSDSDownload (72.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.705
Blood Brain Barrier+0.9601
Caco-2 permeable-0.5258
P-glycoprotein substrateNon-substrate0.8366
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9609
CYP450 2C9 substrateNon-substrate0.8335
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.7384
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9462
CYP450 2C19 inhibitorNon-inhibitor0.9608
CYP450 3A4 inhibitorNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.5617
BiodegradationReady biodegradable0.9734
Rat acute toxicity1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.9888
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionTopical
CapsuleOral667 mg/1
TabletOral667 mg
TabletOral667 mg/1
LiquidIntravenous
SolutionIntravenous
Injection, solution, concentrateIntravenous
SolutionOral667 mg/5mL
Kit
Prices
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USD capsule
Phoslo 667 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6576665 No2001-04-032021-04-03Us
US6875445 No2001-07-302021-07-30Us
US8591938 No2010-02-232030-02-23Us
US8592480 No2007-07-202027-07-20Us
US9089528 No2007-07-202027-07-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point> 160 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility147.0 mg/mLALOGPS
logP0.24ALOGPS
logP-0.22ChemAxon
logS-0.03ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentAcetate salts
Alternative Parents
Substituents
  • Acetate salt
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External Descriptors

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
binder
References
  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. [PubMed:2811066 ]
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. [PubMed:12815333 ]
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. [PubMed:15882308 ]
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. [PubMed:15954948 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39